Author: Daniel Ghinn

What doctors say about the 2017 UK Budget

This post was originally commissioned for PharmaPhorum in July 2017 “Twitter is a much better source of budget analysis for NHS than any news outlet”, Tweeted gastroenterologist Dr Ben White on the afternoon of the Chancellor’s 2017 Budget speech. By now, we’ve all probably read and heard more than enough analysis of the new UK budget, so this is not another of those pieces. Instead, let’s look at what those on the front lines of healthcare delivery have to say about how the budget will affect their work. Here’s a brief analysis of healthcare professionals’ reactions to the budget over the...

Read More

Launch strategies for Business Intelligence

We live in an exciting time of opportunity for pharmaceutical business intelligence professionals. The environment in which we operate has been disrupted by the evolving market, and customer behaviours are changing. This creates a challenge for pharmaceutical planning which can be addressed with business intelligence. But even the business intelligence function must adapt to new customer behaviours if it is to solve today’s challenges. A significant influence on customer behaviours has been the digital age: the Internet and social media have transformed the way health stakeholders learn and interact with each other. Healthcare professionals (HCPs) are learning about innovations...

Read More

Engaging the digital healthcare professional

Some years ago I spoke with an emergency medic who had twenty five years’ experience as a practising doctor. He told me how public social media channels had allowed him to develop an international, collaborative network of peers. Using public social media channels including Twitter was a natural choice for his network of healthcare professionals because, he told me, pharmaceutical companies would never bombard them with messaging in the way he had experienced inside closed doctors’ networks. This may be a challenging lesson for those who still invest heavily in advertising targeted at doctors inside closed networks. The emergency...

Read More

What HCPs say about Roche’s breast cancer drug

In June, NICE – the UK’s health spending policymaker – made a decision to recommend Kadcyla for use in breast cancer, following initial negative draft guidance, published in December 2016, which stated that the product was too expensive for routine funding on the NHS. Until that point, Kadcyla was only available to patients via the Cancer Drugs Fund (CDF), a source of funding with a fixed budget designed to provide fast access to new drugs. But, after Roche agreed to reduce the price of the drug to the NHS in England, NICE issued final guidance recommending it for use. Shortly afterwards it was announced...

Read More

Strategic Planning for Pharma in the Digital Age

Twenty years ago, the Internet promised to change everything. While doctors were starting to get online, set up email and websites, and join forums such as, pharmaceutical companies started to think about their own digital presence. Some companies set up their first website, a new channel for corporate communication. However, the traditional model of customer engagement – pharmaceutical representatives hoping to find a window in a doctor’s schedule for a few minutes of face-to-face time – was largely unchanged. A whole decade later, and some pharmaceutical companies were starting to ask questions about the digital behaviours of their...

Read More

Upcoming Events


The HCP insights eJournal for leaders in healthcare  Subscribe